Claziprotamide

Claziprotamide

Clinical data
Other names	BBP-671
Identifiers
IUPAC name 1-[4-(6-chloropyridazin-3-yl)piperazin-1-yl]-2-(4-cyclopropyl-3-fluorophenyl)ethanone
CAS Number	2361124-03-8
PubChem CID	142616838
ChemSpider	129431674
UNII	74N47PKZ3K
PDB ligand	Y92 (PDBe, RCSB PDB)
Chemical and physical data
Formula	C19H20ClFN4O
Molar mass	374.84 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1CC1C2=C(C=C(C=C2)CC(=O)N3CCN(CC3)C4=NN=C(C=C4)Cl)F
InChI InChI=InChI=1S/C19H20ClFN4O/c20-17-5-6-18(23-22-17)24-7-9-25(10-8-24)19(26)12-13-1-4-15(14-2-3-14)16(21)11-13/h1,4-6,11,14H,2-3,7-10,12H2 Key:GGZFNPBICDFCKG-UHFFFAOYSA-N

Claziprotamide is an investigational new drug that is being evaluated for the treatment of rare metabolic disorders such as pantothenate kinase-associated neurodegeneration (PKAN) and neurodegeneration with brain iron accumulation (NBIA). It acts as a positive allosteric modulator (PAM) of pantothenate kinases 1 and 3 (PANK1 and PANK2) which are critical for coenzyme A biosynthesis and cellular metabolism.